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Advanced glycation endproducts (AGEs) are toxic 
metabolites deriving from reactions between dicarbonyl 
compounds, such as methylglyoxal, and proteins, 
which compromise protein function. AGEs effects are 
counteracted by an enzymatic cycle where glyoxalase 
(Glo)-1, the limiting enzyme of AGEs detoxification, 
catalyses the glutathione (GSH)-dependent conversion of 
methylgyoxal into S-D-lactoylglutathione, which is further 
metabolised to D-lactate by Glo-2.
A pathogenic role for AGEs in neurodegeneration 
has been evidenced by several studies showing that the 
abnormal proteins accumulating in brain in the typical 
lesions of different diseases are glycated. In addition 
to physiological ageing, the cerebral accumulation of 
AGEs can be enhanced by the consumption of saturated 
fat-rich, sugar-added or high temperature-processed 
foods contributing to the precocious onset or accelerated 
progression of neurodegenerative diseases [1,2].
In particular, we recently documented that a 
high fructose intake evokes AGEs accumulation in 
hippocampal neurons related to impaired activity of Glo-
1, and this was associated to mitochondrial dysfunction 
and oxidative stress due to inhibition of nuclear factor-
erythroid 2 p45 subunit-related factor 2 (Nrf2). Nrf2 is 
an essential transcription factor regulating the expression 
of genes containing an antioxidant-response element 
(ARE) responsible for protection against oxidative stress 
and GSH-recycling. Interestingly, in the hippocampus 
of fructose-fed mice, the inhibition of AGEs production 
by the administration of pyridoxamine, able to trap the 
dicarbonyl precursors, also led to restoration of both Glo-1 
and Nrf2 activities, limiting the extension of inflammation 
and oxidative stress [1]. 
In addition to a healthy diet, low in fat, sugar, 
and exogenous AGEs, the possibility to enhance Glo-
1 and Nfr2 activities may slow the progression of 
neurodegeneration. Indeed, studies reporting the positive 
effects of Nrf2 stimulation on mitochondrial dysfunction 
and neurodegeneration have been recently reviewed by 
Esteras and colleagues [3], while the beneficial impact 
of Glo-1 restoration on specific indicators of Alzheimer’s 
disease has been evidenced in a transgenic mouse model 
[4]. In this latter study, the administration of ψ-GSH, a 
synthetic cofactor of Glo-1 resistant to hydrolysis by 
intestinal and hepatic γ-GGTs and able to pass the blood 
brain barrier, reduced cognitive decline, Aβ plaque 
deposition, protein carbonyl content, and reactive oxygen 
species. However, these effects were presumably due in 
part to a general antioxidant effect of GSH replenishing, 
in addition to specific Glo-1 restoration [4]. 
Intriguingly, there are increasing indications of 
a reciprocal influence between Glo-1 and Nrf2: Nrf2 
target genes are involved in GSH recycling providing 
the essential co-factor for Glo-1 enzymatic activity, and 
vice versa, the depletion of GSH by Glo-1 activity can 
act as a stimulating factor for Nrf2 activation. However, 
in condition of excessive AGEs production, which is 
always accompanied by increased oxidative stress, the 
concomitant saturation of Glo-1 detoxifying potential and 
exhaustion of Nrf2 activation might occur.
A previous study also suggests that Nrf2 directly 
regulates the transcription of Glo-1, since the discovery 
of a functional ARE in exon 1 of GLO1 gene has been 
described [5]. In that study, the parallel increase in 
Glo-1 expression and Nrf2 activation was reported in 
in vitro experiments with specific Nrf2 inducers, such 
as sulforaphane, and it was demonstrated that this was 
mediated by interaction of Nrf2 with the regulatory 
region of GLO1 gene [5]. Similarly, hippocampal and 
cerebrocortical cultured neurons exposed to high glucose 
and treated with the natural compound mangiferin, 
renowned for its antioxidant, anti-inflammatory, and 
neuroprotective actions, showed upregulation of Glo-1 
and enhanced activation of Nrf2. The treatment with the 
Nrf2-specfic inducer sulforaphane confirmed the Nrf2-
dependent upregulation of Glo-1 in the same experimental 
conditions [6]. In addition, a very recent study has 
reported the antiparkinsonian effect of vildagliptin in a 
rat rotenone model that was mediated by the concomitant 
suppression of AGE-RAGE, suggestive of a possible Glo-
1 involvement, and induction of Nrf2 signalling pathways 
in the striatus [7]. 
Therefore, the direct control of Glo-1 expression 
level by Nrf2 seemed to be contradicted in our study by 
the increased protein levels of Glo-1, particularly in the 
dimeric form, detected in the hippocampus of fructose-
fed mice, despite Nrf2 nuclear translocation was markedly 
inhibited [1]. The functional implications of the Glo-1 
dimerization and intracellular redistribution, elsewhere 
described [8], would need to be further investigated to 
fully understand the mechanisms of regulation of Glo-1 
activity and expression. Anyway, it could be postulated 
that the accumulation of Glo-1 protein content in brain 
of high fructose mice was due to post-translational 
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modifications that stabilize Glo-1 dimers preventing their 
degradation, independently of both its enzymatic activity, 
which was actually reduced, and possibly reduced mRNA 
expression, that however was not evaluated in our study 
[1]. This hypothesis is sustained by the observation that the 
depletion of Glo-1 activity in early and middle stages of 
Alzheimer’s disease is not associated to a parallel decrease 
in Glo-1 protein level, which on the contrary is transiently 
overexpressed, to progressively decline in late stage [4]. 
In a similar fashion, Nrf2 is temporarily induced by mild 
oxidative stress conditions, for example in early stage of 
diabetes, while with excessive reactive oxygen species 
production the Nrf2-mediated protective mechanism 
undergoes to exhaustion [6]. These observations may thus 
indicate a temporal dynamic reciprocal regulation of Nrf2 
and Glo-1 during disease development. 
In summary, although the interacting mechanisms 
for Nrf2 and Glo-1 activation should be further cleared in 
future addressed studies, emerging evidences indicate that 
the targeting of Nrf2/Glo-1 axis is likely to be a promising 
adjuvant strategy to limit brain AGEs accumulation and 
improve neurons antioxidant potential, and thus slow 
neurodegeneration.
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